CytoMed chairman lifts stake to 25.17%
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
CytoMed Therapeutics Chairman and Director Choo Chee Kong bought 29,250 ordinary shares on the Nasdaq Capital Market between October 12-15, 2026, for roughly $25,117.35. He now beneficially owns 3,003,996 shares, or 25.17% of outstanding shares. The filing notes he and other Glorious Finance Limited shareholders may act as a group with shared voting power, without a formal agreement.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.